GLP1R and metabolic dysfunction-associated steatohepatitis: Given that GLP‐1R is generally expressed in parenchymal cells rather than immune cells,29 most of the reports on the anti‐inflammatory effects of GLP‐1 agonists are considered to be mediated by parenchymal cells such as fibroblasts in arthritis,6 dermal cells in psoriasis,30 and hepatocytes in nonalcoholic steatohepatitis.22